|5.||Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
|1.||Baqar, Shahida: 3 articles (01/2010 - 05/2006)|
|2.||Angulo, Frederick J: 3 articles (04/2007 - 01/2003)|
|3.||Nelson, Jennifer M: 3 articles (04/2007 - 01/2003)|
|4.||McDermott, Patrick F: 2 articles (05/2015 - 10/2013)|
|5.||van Pelt, W: 2 articles (09/2012 - 01/2010)|
|6.||Kopecko, Dennis J: 2 articles (08/2012 - 05/2006)|
|7.||Bray, Mechelle D: 2 articles (08/2012 - 05/2006)|
|8.||Hu, Lan: 2 articles (08/2012 - 05/2006)|
|9.||Mølbak, Kåre: 2 articles (10/2011 - 06/2003)|
|10.||Sanders, J W: 2 articles (12/2008 - 11/2002)|
|1.||Erythromycin (Erycette)FDA LinkGeneric
01/01/2009 - "Overall, erythromycin, which is the drug of choice for treatment of Campylobacter infections in humans, is effective in vitro against 97% of chicken isolates in Grenada."
06/01/1984 - "Double-blind placebo-controlled trial of erythromycin in the treatment of clinical campylobacter infection."
03/01/2011 - "Erythromycin, a macrolide antibiotic, is the first-choice treatment for Campylobacter infections, and failure to eradicate Campylobacter is usually due to macrolide resistance. "
01/01/2010 - "Erythromycin is the proposed drug of choice for the treatment of Campylobacter infections. "
01/01/2010 - "To determine the accuracy of routine tests for erythromycin resistance, 48 erythromycin-resistant isolates from various laboratories that participate in the Dutch surveillance of Campylobacter infections were reinvestigated. "
06/01/2013 - "In our institution, empirical use of fluoroquinolones for Campylobacter infections should not be recommended by the high rate of resistance. "
12/01/1995 - "The in-vitro susceptibility of all species to the fluoroquinolones and the good response observed in early clinical trials has led to the proposal that these agents may be useful in the treatment of campylobacter enteritis and other more complicated campylobacter infections. "
10/01/2013 - "Most Campylobacter infections are self-limiting but antimicrobial treatment (e.g., macrolides, fluoroquinolones) is necessary in severe or prolonged cases. "
12/01/2007 - "The incidence of human Campylobacter infections has increased markedly in both developed and developing countries worldwide and, more significantly, so has the rapid emergence of antibiotic-resistant Campylobacter strains, with evidence suggesting that the use of antibiotics, in particular the fluoroquinolones, as growth promoters in food animals and the veterinary industry is accelerating this trend. "
06/01/2006 - "The incidence of human Campylobacter infections is increasing worldwide, as well as the proportion of isolates resistant to fluoroquinolones and/or macrolides, the drugs of choice to treat campylobacteriosis. "
|4.||DNA (Deoxyribonucleic Acid)IBA
07/01/1995 - "PCR mediated DNA typing was also used to study the epidemiology of diarrheal diseases caused by Campylobacter spp. Using primers complementary to dispersed repetitive DNA sequences and arbitrarily chosen DNA motifs PCR fingerprinting has proven to be a fast, highly discriminative and relatively simple method that can be applied in epidemiological investigations on Campylobacter infections. "
02/01/1994 - "The applicability of polymerase chain reaction (PCR)-mediated DNA typing, with primers complementary to dispersed repetitive DNA sequences and arbitrarily chosen DNA motifs, to study the epidemiology of campylobacter infection was evaluated. "
11/01/1993 - "However, further study is needed to assess the sensitivity and specificity of PCR-mediated DNA analysis and to investigate the usefulness of this method as an epidemiological tool in outbreaks of Campylobacter infections."
01/01/2000 - "jejuni DNA probe could be a useful identification method in epidemiological studies of Campylobacter infection in Nigeria."
09/01/1987 - "The DNA hybridization assay had a sensitivity of 98.7% (75/76) and a specificity of 98.2% (1347/1372) and overall agreed with 98.2% of the conventional results for a test population that had a 5.2% incidence (76/1448) of Campylobacter infection. "
05/01/2004 - "The aims of the present study were to investigate the normal serum response to an acute Campylobacter infection and the sensitivity and specificity of anti-Campylobacter antibodies in determining recent Campylobacter infection. "
02/01/2007 - "Utility of serum Campylobacter specific antibodies in determining prior Campylobacter infection in neurological disease."
07/01/1996 - "Serum samples from 49 patients with campylobacter infection were tested for legionella antibodies using the indirect fluorescent antibody test (IFAT) and the RMAT. "
10/01/1991 - "Patients with anti-glycoconjugate antibodies also had a higher incidence of previous Campylobacter infections than the rest of the patient group, although the significance of this remains to be determined."
10/01/1991 - "Association between glycoconjugate antibodies and Campylobacter infection in patients with Guillain-Barré syndrome."
03/01/2000 - "These three antigens seem to be good candidates for the development of assays suitable for direct and indirect diagnosis of Campylobacter infections."
06/01/2014 - "The objectives of this study were, first, to identify the most specific and sensitive test antigen in an optimized ELISA assay for diagnosing a previous Campylobacter-infection and, second, to compare the prevalence of anti-Campylobacter antibodies in cohorts of healthy blood donors (BD), AE, GBS, RA, and IBD patients with antibodies against known GBS, RA and IBD triggering pathogens. "
10/01/1989 - "An ELISA with an N-terminal synthetic peptide derived from the flagellin protein as antigen was not sensitive (60%) for detecting campylobacter infection but was very specific (97.5%). "
|7.||Rifabutin (Ansamycin)FDA Link
|8.||Gentamicins (Gentamicin)FDA LinkGeneric
05/01/2015 - "This study demonstrated that several new aminoglycoside resistance genes underlie the recent emergence of gentamicin-resistant Campylobacter, and that, in addition to contaminated retail chicken, other sources have also contributed to gentamicin-resistant Campylobacter infections in humans."
04/01/1985 - "The high prevalence of strains resistant to erythromycin suggests chloramphenicol and gentamicin as possible alternative drugs in the treatment of life-threatening Campylobacter infections."
|1.||Transplantation (Transplant Recipients)
06/01/2013 - "In samples from asymptomatic immunocompromised and immunocompetent patients, EPEC but not Norovirus and Campylobacter infections were detected at a frequency similar to that observed in symptomatic kidney transplant recipients. "
02/01/2002 - "Emergence of cotrimoxazole- and quinolone-resistant Campylobacter infections in bone marrow transplant recipients."
|2.||Colonic Pouches (S Pouch)
02/01/2010 - "Campylobacter infection in patients with ileal pouches."
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
02/01/2002 - "Clinical and microbiological data were collected prospectively from 704 patients who underwent bone marrow transplantation (BMT) during an 11-year period (1991-2001), and the first two cases of Campylobacter infection occurring in BMT recipients in the pre-engraftment period were identified. "
|5.||Drug Therapy (Chemotherapy)
06/01/1992 - "[Chemotherapy of Campylobacter infections]."